Plain-English translation of NCT05700617 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether a medication called milrinone can help doctors understand your heart's true strength and predict how you'll do with advanced heart failure treatments. You'll have specialized heart testing (a right heart catheterization) that your doctor has already recommended, and depending on your condition, you may receive the medication during this test to see how your heart responds.
Doctors need better ways to measure the heart's reserve—its ability to pump harder when needed—to predict which advanced treatments (like transplants, heart pumps, or support devices) will work best for each patient. This medication may help reveal that hidden reserve during testing.
You likely qualify if…
You likely don't qualify if…
You will undergo the specialized heart catheterization test your doctor recommended, where thin tubes are guided to your heart to measure pressures and function. Depending on which group you're randomly assigned to and whether you show signs of severe shock, you may receive the medication as a bolus dose during the test, and it may continue as a low-dose infusion if needed. The study team will monitor how your heart responds to better understand your condition and help guide your treatment plan.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Chicago
Enrollment target
~5 participants
Started
July 2023
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
David Onsager, MD
University of Chicago
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.